Status:
COMPLETED
Targeting of Immune Response After Pneumococcal Vaccination
Lead Sponsor:
Helsinki University Central Hospital
Conditions:
Pneumococcal Pneumonia
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine...
Detailed Description
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 1...
Eligibility Criteria
Inclusion
- Males and females ≥ 18 and \<65 years of age.
- General good health.
- Written informed consent.
- No previous vaccination against Pnc
- No previous history of Pnc pneumonia
- In pneumonia: Diagnosis of Pnc pneumonia within a week
Exclusion
- \< 18 years, ≥65 of age.
- In vaccinees: Acute disease at the time of enrollment.
- Pregnancy or lactation.
- Known immunodeficiency or immune suppressive treatment.
- Any chronic illness that might interfere with the immune response
- Alcohol or drug abuse
- Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01402245
Start Date
January 1 2005
End Date
June 1 2010
Last Update
July 26 2011
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Helsinki, Haartman institute, Dept. of Bacteriology and Immunology
Helsinki, Finland, 00014
2
Division of Infectious Diseases, HUCH
Helsinki, Finland, 00029
3
Division of Microbiology, HUSLAB, Helsinki University Central Hospital
Helsinki, Finland, 00029
4
University of Turku
Turku, Finland, 20520